

PRESS RELEASE

18 September 2026 10:40:00 CEST

NOMINATION COMMITTEE FOR INFANT BACTERIAL THERAPEUTICS AB (PUBL) FOR THE ANNUAL GENERAL MEETING 2027

The Nomination Committee for Infant Bacterial Therapeutics AB for the Annual General Meeting 2027 has been appointed based on the ownership structure as of 30 June 2026.

The Nomination Committee for the Annual General Meeting 2027 has been formed in accordance with the decision of the Annual General Meeting. The Nomination Committee consists of David Dangoor (Chairman of the Nomination Committee), appointed by the largest shareholder Annwall & Rothschild Investments AB, Sebastian Jahreskog, who through direct and indirect ownership is the company's second largest shareholder, and Karsten Ferm, appointed by the shareholder Fjärde AP-fonden. In addition, Peter Rothschild is a member of the Nomination Committee in his capacity as Chairman of the Board.

Shareholders wishing to submit proposals to the Nomination Committee are welcome to contact the Chairman of the Nomination Committee by e-mail at derd@derdangoor.com or by letter:

Infant Bacterial Therapeutics AB
Att: Valberedningen
Katarina Bangata 70
116 42 Stockholm, Sweden

For further information, please contact Nigel Titford
Email: nigel.titford@ibtherapeutics.com

Contacts

Staffan Strömberg, CEO
Maria Ekdahl, CFO

info@ibtherapeutics.com

About IBT

Infant Bacterial Therapeutics AB ("IBT") is a public company domiciled in Stockholm. The company's Class B shares are listed on Nasdaq Stockholm (IBTB) since September 10, 2018.

IBT is a pharmaceutical company whose mission is to develop and commercialize drugs for diseases affecting premature babies.

IBT's main focus is the drug candidate IBP-9414, a formulated bacterial strain naturally found in human breast milk. IBP-9414, is expected to be the first product in the new class of biologics called "Live Biotherapeutic Products" for premature infants. The development of IBP-9414 is currently in its final stages.

In the recent Phase III Connection study in premature infants that was completed in July 2024, the group treated with IBP-9414 demonstrated a significant 27% reduction in all-cause mortality compared with the placebo group, meaning that widespread use of IBP-9414 could save more than 1000 patients annually in the US alone. The therapy has received both Breakthrough Therapy Designation (March 2025) for gastrointestinal related mortality and Rare Paediatric Disease Designation, reflecting its potential to address a significant unmet medical need.

The portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP-1016, for the treatment of gastroschisis, a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs. IBP-1118 to prevent retinopathy of prematurity (ROP), one of the leading causes of blindness in premature babies, and IBP-1122 to eliminate vancomycin-resistant enterococci (VRE), which cause antibiotic-resistant hospital infections.

Through the development of these drugs, IBT can address medical needs where no sufficient treatments are available.

Attachments

[NOMINATION COMMITTEE FOR INFANT BACTERIAL THERAPEUTICS AB \(PUBL\) FOR THE ANNUAL GENERAL MEETING 2027](#)